ANTI-CD134(OX40) ANTIBODIES AND USES THEREOF
The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effec...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English Korean |
Published |
09.06.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment. |
---|---|
Bibliography: | Application Number: KR20147010124 |